Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Review the current Madrigal Pharmaceuticals Inc (MDGL:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MDGL is the best investment for you.

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

Short interest in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) increased during the last reporting period, rising from 4.03M to 4.10M. This put 21.43% of the company's publicly available shares ...

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic ...